Description: Catalyst Biosciences, Inc., a biopharmaceutical company, focuses on discovering and developing novel biopharmaceutical products based on engineered human proteases. The company designs its proteases to promote hemostasis and to prevent inflammation. Its pipeline of protease therapeutics include CB 813d/PF-05280602, an engineered Factor VIIa drug candidate that completed a Phase 1 clinical trial evaluating safety and tolerability, as well as pharmacokinetics, pharmacodynamics, and coagulation activity. The company's pre-clinical development stage drugs comprise CB 2679d/ISU 304, a next-generation Factor IX drug for the treatment of hemophilia B inhibitor patients; and an engineered Factor Xa for hemophilia and the control of bleeding in non-hemophilia patients. It also develops factor C3 for the prevention of renal delayed graft function and the treatment of dry age-related macular degeneration. Catalyst Biosciences, Inc. is headquartered in South San Francisco, California.
Home Page: www.catalystbiosciences.com
CBIO Technical Analysis
611 Gateway Boulevard
South San Francisco,
CA
94080
United States
Phone:
650 871 0761
Officers
| Name | Title |
|---|---|
| Dr. Nassim Usman Ph.D. | Pres, CEO & Director |
| Ms. Seline E. Miller CPA | Sr. VP of Fin., Interim Chief Financial & Principal Accounting Officer |
| Dr. Grant Blouse M.Sc., Ph.D. | Chief Scientific Officer |
| Ms. Ana Kapor | Sr. Director of Investor Relations & Corp. Communications |
| Dr. Tom Knudsen D.V.M., Ph.D. | Sr. VP of Corp. Devel. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 1.529 |
| Price-to-Book MRQ: | 0.5274 |
| Price-to-Sales TTM: | 4.8219 |
| IPO Date: | 2006-04-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 45 |